Posted by AGORACOM-JC
at 8:18 AM on Tuesday, October 27th, 2020
For the period beginning July 1st , 2020 and ending September 30th , 2020, Hollister reports that it generated record quarterly revenue of CDN$ 12.5 million and CDN$ 1.265 million in EBITDA from its product line of pre-rolls, concentrates, distillates, solvent-free bubble hash, pre-packaged flower, tinctures and vape products
VANCOUVER, BC , Oct. 27, 2020 – Hollister Biosciences Inc.(CSE: HOLL) (OTC: HSTRF) (FRANKFURT: HOB) (the ” Company “, ” Hollister Cannabis Co .” or ” Hollister “) a diversified cannabis branding company with products in over 280 dispensaries throughout California , and over 80 dispensaries throughout Arizona, is pleased to provide an update on its Q3, 2020 performance.
Q3 2020 Update
For the period beginning July 1 st , 2020 and ending September 30 th , 2020, Hollister reports that it generated record quarterly revenue of CDN$ 12.5 million and CDN$ 1.265 million in EBITDA from its product line of pre-rolls, concentrates, distillates, solvent-free bubble hash, pre-packaged flower, tinctures and vape products. The Company cautions that revenue and EBITDA figures have not yet been audited and are based on reports prepared by management.
“We are very pleased with our ability to deliver record quarterly revenue in such a challenging market environment. We attribute our revenue growth to further penetration of the California and Arizona dispensary networks and successful new product launches with our joint venture partners. We hope to continue this positive momentum into year-end” stated Carl Saling , CEO.
About Hollister Biosciences Inc.
Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products. Our wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker”.
The CSE, nor its regulation services provider, does not accept responsibility for the adequacy or accuracy of this release.
Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com
Posted by AGORACOM-JC
at 6:56 PM on Tuesday, October 20th, 2020
Announced that all of management’s nominees listed in the Company’s management information circular dated September 22, 2020 were elected as directors of the Company at Avicanna’s annual general and special meeting of shareholders held on October 20, 2020.
TORONTO , Oct. 20, 2020 – Avicanna Inc. (” Avicanna ” or the ” Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of cannabinoid-based products, is pleased to announce that all of management’s nominees listed in the Company’s management information circular dated September 22, 2020 were elected as directors of the Company at Avicanna’s annual general and special meeting of shareholders held on October 20, 2020 (the ” Meeting “). The detailed results of the vote for the election of directors held at the Meeting are set out below.
Name of Nominee
Votes cast FOR
% votes cast FOR
Votes WITHHELD
% votes WITHHELD
Aras Azadian
11,304,321
99.94%
7,350
0.06%
Setu Purohit
11,304,321
99.94%
7,350
0.06%
Giancarlo Davila Char
11,304,215
99.93%
7,456
0.07%
Dr. Chandrakant Panchal
11,304,321
99.94%
7,350
0.06%
David Allan White
11,304,721
99.94%
6,950
0.06%
Janet Giesselman
11,304,721
99.94%
6,950
0.06%
Benjamin Leavenworth
11,304,415
99.94%
7,256
0.06%
At the Meeting, the Company’s shareholders also approved the appointment of MNP LLP as the Company’s auditors for the ensuing year, authorized the board of directors to fix the auditors’ remuneration and approved cancellation and re-issuance of certain stock options previously granted to, among others, certain insiders of the Company.
About Avicanna
Avicanna is a diversified and vertically integrated Canadian biopharmaceutical company focused on the research, development, and commercialization of plant-derived cannabinoid-based products for the global consumer, medical, and pharmaceutical market segments.
Avicanna is an established leader in cannabinoid research and development, which it primarily conducts at its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, Canada and in collaboration with leading Canadian academic and medical institutions. In addition to its developing pharmaceutical pipeline, Avicanna’s team of experts have developed and commercialized several industry leading product lines, including:
Pura H&W™: an advanced and clinically tested line of CBD consumer derma-cosmetic products; and,
RHO Phyto™: an advanced line of medical cannabis products containing varying ratios of CBD and THC currently available nation-wide across Canada in partnership with Medical Cannabis by Shoppers™, a subsidiary of Shoppers Drug Mart. RHO Phyto is the first strictly medical formulary of advanced “Cannabis 2.0” products, containing oils, sprays, capsules, creams, and gels, all developed with scientific rigour, manufactured under GMP standards and supported by pre-clinical data.
With ongoing clinical trials on its derma-cosmetic (Pura H&W), medical cannabis (RHO Phyto) and a pipeline of pharmaceutical products, Avicanna’s dedication to researching the important role that cannabinoids play in an increasingly wider scope of products has been at the core of the Company’s vision since its inception. Furthermore, Avicanna’s commitment to education is demonstrated through its annual medical symposium, the Avicanna Academy educational platform, and the My Cannabis Clinic patient program through its subsidiary company.
Avicanna manages its own supply chain including cultivation and extraction through its two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia. Through these sustainable, economical, and industrial scale subsidiaries, Avicanna cultivates, processes, and commercializes a range of cannabis and hemp cultivars dominant in CBD, CBG, THC, and other cannabinoids for use as active pharmaceutical ingredients. Avicanna’s Avesta Genetica program specializes in the development and optimization of rare cultivars for commercial production along with feminized seeds for global export. In June 2020, Avicanna made history with a shipment of hemp seeds to the United States of America by completing the first ever export of hemp seeds from Colombia.
Stay Connected
For more information about Avicanna, visit www.avicanna.com , call 1-647-243-5283, or contact Setu Purohit , President by email [email protected] .
Posted by AGORACOM-JC
at 2:44 PM on Wednesday, October 14th, 2020
SPONSOR: Avicanna (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) is a Canadian vertically-integrated biopharmaceutical company developing and commercializing various cannabinoid-based products for the global market place. When we say vertically integrated, we mean it. Avicanna has 4 fully operating divisions to address the entire market for Cannabis products. As a Cannabis investor, why limit yourself to a Company with just one specialty, when Avicanna offers you exposure to the entire vertical. Learn More.
CBD Skin Care Market Is Booming Worldwide with Strong Growth
Multi-functional attributes such as powerful antioxidants and anti-inflammatory properties of Cannabidiol (CBD) driving the demand for CBD skincare products. It is useful in the treatment of eczema, psoriasis, and acne. The market has high growth prospects owing to rising awareness about skin healing properties of CBD and growing preference for sustainable skincare products. Moreover, the growing online distribution channels for CBD skincare products expected to drive the product demand during the forecasted period.This growth is primarily driven by Rising Awareness about Skin Healing Properties of CBD and Growing Preference for Sustainable Skin Care Products.
AMA Research have added latest edition of survey study on CBD Skin Care Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data. The research study provides estimates for CBD Skin Care Forecast till 2025*.
Important Features that are under offering & key highlights of the report:
1) How Study Have Considered the Impact of COVID-19 / Economic Slowdown of 2020 ?
Analyst at AMA are constantly gathering and conducting survey with opinion leaders and Industry experts from various region to minutely understand impact on growth as well as local reforms to evaluate study and market estimates. Due to lockdown different online medium and procedures are followed like Survey Monkey, LinkedIn Connections, and Email reach and industry forum to established industry viewpoint to garner rich insights for study. A special chapter in the study presents Impact Analysis of COVID-19 on CBD Skin Care Market along with tables and graphs related to various country and segments showcasing impact on growth trends.
2) Can list of players be customize according to targeted regional geographies to match business objective?
Considering heat map analysis and based on market buzz or voice the profiled list of companies in the report are ” Kiehl’s LLC (United States), Cannuka LLC (United States), Elixinol Global Limited (Australia), Medical Marijuana Inc. (United States), Endoca LL (Netherland), Lord Jones (United States), Kapu Maku LLC (United States), Leef Organics (United States), FAB CBD (United States), IRIE CBD (United States) and Kazmira (United States)”. Yes, further list of players can also be customized as per your requirement keeping in mind your areas of interest and adding local emerging players and leaders from targeted geography.
3) Can Market be broken down by different set of application and types?
Additional segmentation / Market breakdown is possible subject to data availability, feasibility and depending upon timeline and toughness of survey. However a detailed requirement needs to be prepared before making any final confirmation.
** 3+ Additional country of your interest can be included at no added cost feasibility test would be conducted by Analyst team of AMA based on the requirement shared and accordingly deliverable time will also be disclosed.
Market Drivers
Rising Awareness about Skin Healing Properties of CBD
Growing Preference for Sustainable Skin Care Products
Market Trend
Growing Acceptance of CBD Products
Restraints
Stringent Government Regulations Regarding CBD Product Manufacturing
Posted by AGORACOM-JC
at 3:39 PM on Thursday, October 8th, 2020
Despite the collapse of marijuana and cannabis related stocks in the last 18 months, there is no denying that Cannabis related products are going to go through a paradigm shifting, parabolic growth stage around the world over this decade for the following reasons:
Cannabis legalization is gaining momentum around the world.
Momentum is primarily driven by the realization that cannabis may have a range of medicinal, therapeutic and wellness applications.
It is the most widely cultivated, consumed and trafficked drug worldwide (United Nations Office on Drugs and Crime).
So what is this going to translate into?
The global cannabis market size was valued at $US 10.6 Billion in 2018 and is projected to reach $97.5 Billion by the end of 2026, a CAGR of 32.92%(Fortune Business Insights)
WHY WILL THIS TIME BE DIFFERENT?
Big promises, big IR budgets, big hype …. Big Letdown.
That pretty much sums up the last cycle of Cannabis related companies that focused on speed, stories and stock prices rather than the one simple but important thing they should have been doing – building a real business.
Investors will remember that the same thing happened during the dot-com era. As with the cannabis collapse over the last 18 months, what followed back in 2000 was a long period of mourning in which many investors had sworn off tech stocks, just as they have with cannabis stocks today.
But it wasn’t long until tech investors dusted themselves off and realized tech was here to stay – but this time they were only going to focus on real companies with real businesses. What we got was Amazon, Google, Linkedin, Facebook and then the rest was history.
The same thing is about to happen to the Cannabis sector
Meet the 8 new horsemen of the next leadership group that are firing on all cylinders (in alphabetical order).
Avicanna (AVCN :TSX) (AVCN : OTCQX) ( 0NN: FSE) is a vertically-integrated biopharmaceutical company developing and commercializing various cannabinoid-based products for the global marketplace.
When we say vertically integrated, we mean it. Avicanna has 4 fully operating divisions to address the entire market for Cannabis products as follows:
1. The company has a full line of high end CBD based skin care products serving the consumer retail segment with Canadian distribution through Medical Cannabis by Shoppers, as well as global distribution later this year. These are the only known CBD cosmetics backed by clinical trials.
2. Avicanna’s superior medical cannabis line also features products distributed through Medical Cannabis by Shoppers, the online arm of Canada’s largest drugstore chain. In addition, the company recently received certification and authorization for the sale of pharmaceutical cannabinoid products with medical prescriptions in Colombia.
3. Avicanna also hosts a full pipeline of Pharmaceuticals in various stages of trials to address Dermatology, Psychiatry, Neurology, Pain and Oncology. Three of the company’s products are already as far as phase 2.
For more information about the company, please check out the Avicanna HUB on AGORACOM.
Empower (CBDT: CSE) (EPWCF:OTCQB) (8EC:Frankfurt) is a vertically integrated, multi-state operator of medical clinics with a database of over 165,000 patients, a database that almost every medical cannabis and CBD company would kill for … but then these numbers recently came in for the first two quarters to further cement Empower as a leader:
PatientVisits
Q1 + 377% To 5,717
Q2 + 56% To 6,696
Revenues $USD
Q1 + 416% To $790,000 (NO COVID)
Q2 + 56% To $923.000
TOTAL Q1 AND Q2
REVENUE $1.7M vs $745K = + 130%
PATIENTS 12,400 vs 5,500 = + 125%
NET LOSS $920K vs 1.85M = – 50%
Empower has now delivered growth in 4 successive financial reports (Q4, FY 2019, Q1 and Q2), so it is safe to say that superstar CEO Steve McAuley can officially claim victory on the turnaround he inherited in 2019.
BONUS – The Company’s physician staffed clinics have are also generating significant revenue and growth from the COVID-19 pandemic as follows:
Increased CBD treatments from patients suffering increased anxiety;
Testing for individuals and families
Testing for local businesses and employees
Testing for enterprise level organizations across the country
At the lowest price of $USD 80 per test and operating on just 1,000 tests per day, the clinic would deliver $USD 80,000 in revenue PER DAY
Oh, and did we mention that CEO Steven McAuley is Six Sigma certified under the quality initiative of legendary GE (General Electric) Chairman Jack Welch? We’ve never seen a Six Sigma certified CEO in the Canadian small cap markets. Never. Which explains how McAuley has been able to guide Empower Clinics through the most disruptive retail environment in recent history and turn it into significant growth.
For more information about the company, please check out the Empower HUB on AGORACOM.
Harborside (HBOR: CSE), (HSDEF: OTCQX) has generated over $400,000,000 (NOT a typo) since its inception in 2006. We thought that would get your attention.
What Do They Do?
HBOR is a California-focused, vertically integrated, fully licensed cannabis company with its business consisting of three primary segments:
1. Retail Dispensaries
2. Wholesale
3. Cultivation and Processing
HIGHLIGHTS
Founded in 2006. One of the oldest and most respected cannabis retailers in California
Awarded one of the first six medical cannabis licenses in the USA
Operations have generated over $400M in cumulative sales since inception
Retail operations command 3% of California’s entire retail market
2020 Financials (Q1 + Q2)
○ Revenues $30,800,000
○ Gross Profit $14,000,000
○ EBITDA $1,100,000
Expected to generate approximately $62M – $65M in sales in 2020
Operate California’s only drive-through dispensary
Over 1,300 customers per day in Q2
Oakland dispensary is one of the largest retail cannabis locations in the world
2020E Guidance
~$44M Retail Revenue
~$21M Wholesale Revenue
~$62M – ~65M Total Revenue
For more information about the company, please check out the Harborside Inc hub on AGORACOM.
Hollister Biosciences Inc. (HOLL:CSE) (HSTRF:OTC) (HOB: FRANKFURT) is a multi-state cannabis company with products in 230 dispensaries throughout California and over 80 dispensaries throughout Arizona, translating into the following great success:
Revenues $USD
Q1 +317% YoY to $862,000
Q2 +3685% YoY to $8,500,000
TOTAL Q1 AND Q2
REVENUE $9.4M vs $428K = + 2096%
GROSS PROFIT $1.2M vs ($133K) = + 1002%
In addition to organic sales, Hollister has several high-level partnerships that demonstrate how trusted the Company is within the industry, including:
Hollister is also the creator of California’s most hash-infused pre-roll HashBone
For more information about the company, please check out the Hollister Biosciences Inc. hub on AGORACOM.
Innocan Pharma Corporation (INNO: CSE) (IP4:FSE) is developing the pharmaceutical guided missile to defeat coronavirus lung infections. The company specializes in the development of new drug platforms which combine unique properties of Cannabinoids.
3 Fully Operating Divisions For Investor Diversification
Innocan has 3 fully operating divisions to address the market for Cannabis products. As a Cannabis investor, why limit yourself to a Company with just one specialty, when Innocan offers you exposure to both the exploding world of cannabis pharma, as well as, a portfolio of patent-pending and launch ready consumer health products.
PHARMACEUTICAL – THE GUIDED MISSILE – Revolutionary technology targeting lungs infected with coronavirus or other viral infections.
CONSUMER RETAIL – DERMA COSMETICS – A premium derma cosmetics brand, manufacturing has commenced with distribution agreements in place.
OVER THE COUNTER (OTC) PRODUCTS FOR PAIN RELIEF – patent-pending CBD pain relief brand received FDA technical validation.
Global Manufacturing / Distribution Agreements
Endless Sky Inc. a Canadian large scale Cannabis extractor (Manufacturing and Distribution – Canada)
Active Therapeutics Ltd of Lancashire, United Kingdom (Distribution – UK and Ireland markets)
Superior Management Team
In the small cap world, the jockey(s) that drive the horse are just as important as the horse itself. The InnoCan Leadership Group Is Incomparable In The Small Cap World, Comprised Of Leading Israeli Pharmaceutical Executives including:
Executive Chairman (Ron Mayron) was the CEO Of Teva Israel, one of the largest generic pharmaceutical companies in the world
Co-Founder & VP Business Development (Yoram Drucker) was the Founder of 2 NASDAQ Companies (Pluristem & Brainstorm)
Chief Technology Officer (Nir Avram) is a former member of the pharma innovation team at Perrigo, producer of OTC consumer goods and specialty pharma.
Chief Executive Officer (Iris Bincovich) has a proven track record in opening global markets, having managed hundreds of successful transactions in OTC, cosmetics and dermatology.
Together they have built one of the most formidable teams in the small cap cannabis world
For more information about the company, please check out the Innocan Pharma Corporation hub on AGORACOM.
Spyder Cannabis Inc. (SPDR :TSXV) is a Cannabis, Vape and CBD retailer with three retail business units.
SALE OF CANNABIS PRODUCTS – The Company has TWO cannabis dispensaries currently in operation. The first being a location in Calgary, Alberta and the second in Niagara Falls. Both dispensaries are located in busy commercial hubs. The management team is currently evaluating several additional locations in both Alberta and Ontario where it intends to expand the Spyder Cannabis brand’s footprint.
SALE OF HEMP CBD (US) Company is also pursuing the sale of Hemp based CBD products from locations in the USA.
SMOKING CESSATION PRODUCTS IN ONTARIO The company sells electronic cigarettes, E-juice and accessories for the “vape” business from five Canadian retail locations; Woodbridge, Scarborough, Pickering, Niagara Falls and Burlington, Ontario. Spyder has established itself as a savvy retailer.
For more information about the company, please check out the Spyder Cannabis hub on AGORACOM.
Thoughtful Brands, Inc. (TBI: CSE)( 1WZ1: FWB)( PEMTF: OTCQB) is a global natural health products and eCommerce technology company that is operating at full throttle.
Acquired eCommerce retailers with combined total sales of approximately $29,000,000 with an EBITDA of approximately 12.5%.
Current customer base of over 200,000 customers with additional leads of over 600,000 potential new customers
Enhanced eCommernce solution through Unified Funding’s software which facilitated over $350 million in consumer transactions (CAD $93.8 million) in 2019 from more than one million paying customers.
Low-cost production will be vertically integrated into retail brands to achieve up to 20x margin increase.
We’ll let these revenue numbers speak for themselves.
August 2020 CAD $3,809,000
July 2020 CAD $2,340,000
June 2020 CAD $2,712,000
The above represents an increase of 19%, over the same period in 2019.
QUARTERLY REVENUE $CAD
Q1 $7,600,000 Growth
Q2 $12,800,000 Growth
TOTAL Q1 AND Q2
REVENUE $20,400,000
GROSS PROFIT $2,154,357
The company has its sights set on European expansion through a joint venture with Franchise Cannabis Corp. The company will now sell and market Franchise-manufactured CBD, hemp and cosmetic products in the European Union, Switzerland, Norway and the UK, utilizing its eCommerce platform.
The company also completed acquisition of Verrian, which owns and operates a 110,000-square foot pharmaceutical manufacturing facility in Radebuel, Germany. This acquisition will assist the company in tapping into the burgeoning market for psychedelics as Verrian specializes in developing psychedelic derived medicines for treatments for addictions, including opioids and alcohol.
For more information about the company, please check out the Thoughtful Brands hub on AGORACOM.
TransCanna (TCAN:CSE) (TH8:FSE) owns a 196,000 square foot cannabis Facility, the largest known fully licensed cannabis facility in California.
CAD$24.9M Revenue Run Rate from 10,000 sq.ft test facility
CAD $90M Annual Revenue expected from first full year of production at Fully Licensed Daly Street Facility.
Acquired two California companies,
High-end award winning edible producer Soldaze
Premium indoor cultivator and distributer Lyfted Farms
Lyfted Farms products sold in select Cookies Locations – The most recognizable name in high-end Cannabis.
2019 California Cannabis sales over $3B, industry currently fragmented
Direct to dispensary model, cutting out the middleman
REVENUES $CAD
Q1 $906,000
Q2 $4,300,000
TOTAL Q1 AND Q2
REVENUE $5,206,000
GROSS MARGIN $1,920,000
For more information about the company, please check out the TransCanna hub on AGORACOM.
Thanks for reading and discovering these great small cap cannabis companies. Please be sure to visit the AGORACOM Small Cap Cannabis Gateway often to stay up to date with new companies at:
Avicanna is a Canadian vertically-integrated biopharmaceutical company developing and commercializing various cannabinoid-based products for the global market place. When we say vertically integrated, we mean it. Avicanna has 4 fully operating divisions to address the entire market for Cannabis products. As a Cannabis investor, why limit yourself to a Company with just one specialty, when Avicanna offers you exposure to the entire vertical. LEARN MORE.
Posted by AGORACOM-JC
at 9:13 AM on Thursday, October 8th, 2020
Provides update regarding the deployment of Lyfted Farms’ Crop Services Management Division (or “LFCSMD”) and the contractual agreement to manage the multi-acre commercial cannabis greenhouse facility in Stanislaus County, CA on behalf of Central Valley Growers (previously announced April 21, 2020)
Construction has commenced in Patterson, California, for a new 22,000 sq.ft. cultivation facility to be managed and operated by LFCSMD
“This is an additional revenue vertical that we intend to perfect and expand, we are very excited to work with the Central Valley Growers team and build a mutually prosperous business”, said TransCanna CEO Bob Blink
Vancouver, British Columbia–(October 8, 2020) – TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) (“TransCanna” or the “Company”) is pleased to provide an update regarding the deployment of Lyfted Farms’ Crop Services Management Division (or “LFCSMD”) and the contractual agreement to manage the multi-acre commercial cannabis greenhouse facility in Stanislaus County, CA on behalf of Central Valley Growers (previously announced April 21, 2020). Operating under the wholly-owned subsidiary, Lyfted Farms Inc., construction has commenced in Patterson, California, for a new 22,000 sq.ft. cultivation facility to be managed and operated by LFCSMD.
LFCSMD is very pleased to announce the finalized contract with Central Valley Growers to be the sole operator and distributor for the new state of the art facility. The first phase of operations is scheduled to OPEN January 1, 2021.
“This is an additional revenue vertical that we intend to perfect and expand, we are very excited to work with the Central Valley Growers team and build a mutually prosperous business”, said TransCanna CEO Bob Blink, “Lastly, I am very proud of all parties for staying engaged through the current COVID 19 pandemic, working through the challenges to keep this opportunity moving forwards”, Blink adds.
Central Valley Growers CEO Nav Singh remarks, “we are very excited to see the execution of our partnership with Lyfted Farms, they have an outstanding reputation for cultivating in-demand genetics, and it creates more certainty once product is ready for market.” LFSCMD ‘Higher Standard Farm Management Agreement’ includes the provision of genetic stock, crop cultivation, labor, compliance oversight, and distribution of finished product over an initial 5-year term.
About TransCanna Holdings Inc.
TransCanna Holdings Inc. is a California based, Canadian listed Company building cannabis-focused brands for the California lifestyle through its wholly-owned California subsidiaries.
On behalf of the Board of Directors Bob Blink, CEO 604-349-3011
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs regarding future events of management of the Company. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. This information and these statements referred to herein as “forward-looking statements”, are not historical facts, are made as of the date of this news release and include without limitation estimates and forecasts and statements as to management’s expectations for growth and the commencement of operations of the Company’s Daly facility.
The forward-looking information in this press release is based upon certain assumptions that management considers reasonable in the circumstances, including that operations will commence at the Company’s Daly facility in Modesto, California, as and when expected.
These forward-looking statements involve numerous known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially from any future results, events or developments expressed or implied by such forward-looking statements. Risks and uncertainties associated with the forward-looking information in this news release include, among others, dependence on obtaining and maintaining regulatory approvals, including state, local or other licenses and any inability to obtain all necessary governmental approvals licenses and permits to complete upgrades to its Daly facility in a timely manner; engaging in activities which currently are illegal under U.S. federal law and the uncertainty of existing protection from U.S. federal or other prosecution; regulatory or political change such as changes in applicable laws and regulations, including U.S. state-law legalization, particularly in California, due to inconsistent public opinion, perception of the medical-use and adult-use marijuana industry, bureaucratic delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth;; reliance on management; and the effect of capital market conditions and other factors (including those related to the COVID-19 pandemic) on capital availability; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with customers and suppliers.
Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look, except in accordance with applicable securities laws.
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN
Posted by AGORACOM-JC
at 11:05 AM on Wednesday, October 7th, 2020
SPONSOR: Avicanna (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) is a Canadian vertically-integrated biopharmaceutical company developing and commercializing various cannabinoid-based products for the global market place. When we say vertically integrated, we mean it. Avicanna has 4 fully operating divisions to address the entire market for Cannabis products. As a Cannabis investor, why limit yourself to a Company with just one specialty, when Avicanna offers you exposure to the entire vertical. Learn More.
Growing Adoption of CBD Pharmaceutical Grade and Wellness Products Having Healthy Impact on Market Growth
Global CBD and CBD oil market revenues are projected to continue to rise significantly in the coming years
Increasing consumer preference for various cannabidiol infused products such as capsules, cannabis oil, beverages, beauty and skincare products, gummies, and dog treats is further anticipated to drive the CBD oil and CBD consumer health market
PALM BEACH, Fla., Oct. 1, 2020– The global CBD and CBD oil market revenues are projected to continue to rise significantly in the coming years. Increasing consumer preference for various cannabidiol infused products such as capsules, cannabis oil, beverages, beauty and skincare products, gummies, and dog treats is further anticipated to drive the CBD oil and CBD consumer health market. Cannabidiol can enter the body in several ways such as vaping, ingesting, smoking, and through the skin. Growing adoption of cannabidiol to manufacture medical drugs and personal care products in states where cannabis is legal is positively impacting the market growth. The legalization of cannabis-based products has provided a remarkable opportunity for the end-user industries to expand. The growing number of research activities, increasing awareness regarding synthetic cannabidiol, and rising strategic investments by companies are expected to contribute to the overall growth through 2027.
Posted by AGORACOM-JC
at 8:16 AM on Tuesday, October 6th, 2020
On September 23 rd , 2020, Venom achieved the first revenue milestone by generating in excess of CDN$30,000,000 of revenue calculated from January 1 st , 2020
100% owned subsidiary, Venom Extracts achieved the first of two revenue milestones in accordance with the terms of the definitive agreement
As a result, the Company will issue 19,740,036 common shares to certain former Venom shareholders at a deemed price of $0.20 per Earn-Out Share
VANCOUVER, BC , Oct. 6, 2020 – Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) (Frankfurt: HOB) (the ” Company “, ” Hollister Cannabis Co .” or ” Hollister “) a diversified cannabis branding company with products in over 230 dispensaries throughout California , and over 80 dispensaries throughout Arizona , is pleased to announce that further to the news release dated March 30 th , 2020, its 100% owned subsidiary, Venom Extracts (” Venom “) has achieved the first of two revenue milestones in accordance with the terms of the definitive agreement that was entered in connection with the acquisition of Venom by the Company (the ” Transaction “).
On September 23 rd , 2020, Venom achieved the first revenue milestone by generating in excess of CDN$30,000,000 of revenue calculated from January 1 st , 2020. As a result, the Company will issue 19,740,036 common shares (the ” Earn-Out Shares “) to certain former Venom shareholders at a deemed price of $0.20 per Earn-Out Share. The Earn-Out Shares will not be subject to any hold period under applicable securities laws.
“We are very pleased with the performance of the Arizona team in their ability to achieve this key milestone so expeditiously,” shared Carl Saling , CEO of Hollister .
None of the securities to be issued pursuant to the Transaction have been or will be registered under the U.S. Securities Act of 1933, as amended (the ” U.S. Securities Act “), or any state securities laws, and any securities issued pursuant to the Transaction are anticipated to be issued in reliance upon available exemptions from such registration requirements pursuant to Rule 506(b) of Regulation D and/or Section 4(a)(2) of the U.S. Securities Act and applicable exemptions under state securities laws. In addition, the securities issued under an exemption from the registration requirements of the U.S. Securities Act will be “restricted securities” as defined under Rule 144(a)(3) of the U.S. Securities Act and will contain the appropriate restrictive legend as required under the U.S. Securities Act.
About Hollister Biosciences Inc.
Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products. Our wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker”.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com
When we say vertically integrated, we mean it. Avicanna has 4 fully operating divisions to address the entire market for Cannabis products. As a Cannabis investor, why limit yourself to a Company with just one specialty, when Avicanna offers you exposure to the entire vertical.
CONSUMER RETAIL – COSMETICS
The Only Known CBD Cosmetics Backed By Clinical Trials
Full Line Of High End CBD Based Skin Care Products
Already Commercializing In Colombia
Global Distribution In H2 2020 In United States, Europe and Canada
Canadian Distribution Through Shoppers Drug Mart
MEDICAL CANNABIS
Medical Cannabis 2.0 – Superior Products To Products Currently On The Market
Evidence Backed Medical Cannabis So Doctors Can Prescribe With Confidence
Full Launch Across Canada Immanent
Exclusive Distribution Through Online Store Of Shoppers Drug Mart
RHO Phyto “Micro Drop” oil formulations are the first of the RHO Phyto formulary of advanced medical cannabis products available for patients and health care practitioners
Obtained GPP certification and authorization by INVIMA for the compounding and sale of pharmaceutical cannabinoid products with medical prescriptions in Colombia
Global Distribution Through US, U.K, Australia and Canada In H2 2020
PHARMACEUTICALS
A Full Pipeline Of Pharmaceuticals In Various Stages Of Trials To Address Dermatology, Psychiatry, Neurology, Pain and Oncology
3 Products Already As Far As PHASE 2
CULTIVATION
500,000 Sq Ft Of Low Cost and USDA certified Organic Cannabis Cultivation In Colombia
First Ever Export Of Feminized Hemp Seeds From Colombia (To United States). 7,000,000 Seeds For $380,000
Additional 75,000,000 Seeds Available For Export In Several Pending Transactions
Posted by AGORACOM-JC
at 3:32 PM on Wednesday, September 23rd, 2020
Announced that its Calgary Cannabis dispensary located at 140-104 58 Avenue SE, will be open for business effective Saturday, September 26, 2020
“The Spyder team is excited to commence operations at its second location and bring its best of class customer service and retail experience to one of Calgary’s busiest commercial hubs,” stated Dan Pelchovitz, the company’s CEO.
Company is also currently looking at several additional locations in both Alberta and Ontario where it intends to expand the Spyder Cannabis brand’s footprint
Vaughan, Ontario–(September 23, 2020) – Spyder Cannabis Inc. (TSXV: SPDR) (“Spyder” or the “Company”) and its wholly-owned associated applicants, The Green Spyder Inc. and Spyder Cannabis Subco Inc., is pleased to announce that its Calgary Cannabis dispensary located at 140-104 58 Avenue SE, will be open for business effective Saturday, September 26, 2020.
“The Spyder team is excited to commence operations at its second location and bring its best of class customer service and retail experience to one of Calgary’s busiest commercial hubs,” stated Dan Pelchovitz, the company’s CEO.
The company is also currently looking at several additional locations in both Alberta and Ontario where it intends to expand the Spyder Cannabis brand’s footprint.
About Spyder Cannabis Inc.
Spyder is a Cannabis, Vape and CBD retailer that operates in jurisdictions where the products are federally legal in both Canada and the United States. The Company, through its subsidiaries, is a retailer involved in the development of three retail business units. The first is the sale of Cannabis products, the second is the sale of Hemp CBD in the United States only, the third is the sale of smoking cessation products in Ontario.
For more information, please contact: Dan Pelchovitz 905-265-8273
Cautionary Statements
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release includes statements containing certain ‘forward-looking information” within the meaning of applicable securities laws (‘forward-looking statements”). Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur.
